Gaithersburg, Maryland – May 18, 2020: – MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announces that clinical data from the first three cohorts of the ongoing Phase I dose-escalation trial demonstrating safety of MCY-M11 and feasibility of one-day manufacturing will be shared at the American Society of Clinical Oncology’s (ASCO) upcoming annual meeting. The ASCO20 Virtual Scientific Program will be held May 29-31, 2020.
The Poster Discussion presentation, entitled Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma, will be available in the Developmental Therapeutics: Immunotherapy session, which can be accessed on demand beginning at 8 a.m. ET on Friday, May 29, 2020.
MCY-M11 is a wholly-owned, non-viral, mRNA-based cell therapy candidate manufactured using un-manipulated peripheral blood mononuclear cells. It is under development for the treatment of ovarian cancer and peritoneal mesothelioma. The ongoing study so far demonstrates both the safety and of MCY-M11 as well as the feasibility of one-day manufacturing and intraperitoneal delivery of our cell product.
“This is a presentation of the preliminary results of our ongoing first-in-human study with the novel mRNA-based CARMA platform designed to treat malignancies expressing mesothelin,” said Christina M. Annunziata, MD, PhD, Investigator at the Women’s Malignancies Branch and Head of the Translational Genomics Section at the National Cancer Institute Center for Cancer Research. “We have so far demonstrated the feasibility to deliver MCY-M11 CARMA cells intraperitoneally to treat patients, the acceptable overall safety of using a transient CAR expression approach and early evidence that supports moving forward with and further building on this strategy.”
Click here to read the entire press release.